医学
宫颈上皮内瘤变
妇科
细胞学
人乳头瘤病毒
产科
宫颈癌
风险评估
癌症
内科学
病理
计算机安全
计算机科学
作者
Maria Demarco,Didem Egemen,Noorie Hyun,Xiaojian Chen,Anna‐Barbara Moscicki,Liana Cheung,Olivia Carter‐Pokras,Anne Hammer,Julia C. Gage,Megan A. Clarke,Philip E. Castle,Brian Befano,Jie Chen,Cher M. Dallal,Xinxin He,Kanan Desai,Thomas Lorey,Nancy Poitras,Tina Raine‐Bennett,Rebecca B. Perkins,Nicolas Wentzensen,Mark Schiffman
出处
期刊:Journal of Lower Genital Tract Disease
[Ovid Technologies (Wolters Kluwer)]
日期:2022-03-07
卷期号:26 (2): 127-134
被引量:9
标识
DOI:10.1097/lgt.0000000000000667
摘要
Objective The US screening and management guidelines for cervical cancer are based on the absolute risk of precancer estimated from large clinical cohorts and trials. Given the widespread transition toward screening with human papillomavirus (HPV) testing, it is important to assess which additional factors to include in clinical risk assessment to optimize management of HPV-infected women. Materials and Methods We analyzed data from HPV-infected women, ages 30–65 years, in the National Cancer Institute–Kaiser Permanente Northern California Persistence and Progression study. We estimated the influence of HPV risk group, cytology result, and selected cofactors on immediate risk of cervical intraepithelial neoplasia grade 3 or higher (CIN 3+) among 16,094 HPV-positive women. Cofactors considered included, age, race/ethnicity, income, smoking, and hormonal contraceptive use. Results Human papillomavirus risk group and cytology test result were strongly correlated with CIN 3+ risk. After considering cytology and HPV risk group, other cofactors (age, race/ethnicity, income, smoking, and hormonal contraceptive use) had minimal impact on CIN 3+ risk and did not change recommended management based on accepted risk thresholds. We had insufficient data to assess the impact of long-duration heavy smoking, parity, history of sexually transmitted infection, or immunosuppression. Conclusions In our study at the Kaiser Permanente Northern California, the risk of CIN 3+ was determined mainly by HPV risk group and cytology results, with other cofactors having limited impact in adjusted analyses. This supports the use of HPV and cytology results in risk-based management guidelines.